Artificial intelligence to enhance drug discovery

Cambridge-based drug discovery company Amedis Pharmaceuticals and Argenta Discovery, of Harlow, have signed a collaboration agreement to focus on the application of Amedis' novel artificial intelligence (AI) technology platform to further enhance Argenta's drug discovery processes. Amedis has developed proprietary technologies in both in silico prediction of drug properties and in the chemical modification of drugs to provide better drug-like properties. The two technologies provide a powerful synergistic combination, allowing earlier and better insight into discovery and development problems.

Dr Chris Newton, cso of Argenta Discovery, said: 'The power of the parallel optimisation paradigm which Argenta applies to its contract and IP research projects can only be enhanced by successful applications of new technologies, particularly those devoted to the issues of compound bioavailability and toxicity such as the AI applications of Amedis.'